ReviewOncotarget2011
New perspectives on the role of vitiligo in immune responses to melanoma.
Review in Oncotarget, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.Cancer immunology, immunotherapy : CII · 2016Pooled it
- Immune Checkpoint Inhibitor Data in Metastatic Melanoma with Pre-Existing Autoimmune Disease: A Real World Experience.International journal of molecular sciences · 2026Article
- Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The immunology of vitiligo.Nature reviews. Immunology · 2026Review
- Simultaneous occurrence of cutaneous melanocytic neoplasia in Duroc and German Saddleback pigs from three smallholder farms.BMC veterinary research · 2025Article
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.Heliyon · 2025Article
- Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.International journal of molecular sciences · 2024Review
- The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.Japanese journal of clinical oncology · 2024Review
- Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore.Diagnostics (Basel, Switzerland) · 2024Article
- Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma.Cell reports · 2023Article
- Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.American journal of clinical dermatology · 2023Article
- Article
- Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report.Frontiers in oncology · 2023Article
- Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.Scientific reports · 2022Article
- Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.Cancers · 2022Review
- Basal cell carcinoma: Comprehensive clinical and histopathological aspects, novel imaging tools and therapeutic approaches (Review).Experimental and therapeutic medicine · 2022Review
- Reduced risk of skin cancer and internal malignancies in vitiligo patients: a retrospective population-based cohort study in Taiwan.Scientific reports · 2021Article
- Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.Biomaterials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Melanoma-associated vitiligo is the best-studied example of the linkage between tumor immunity and autoimmunity. Although vitiligo is an independent positive prognostic factor for melanoma patients, the autoimmune destruction of melanocytes was long thought to be merely a side effect of robust anti-tumor immunity. However, new data reveal a key role for vitiligo in supporting T cell responses to melanoma. This research perspective reviews the history of melanoma-associated vitiligo in patients, the experimental studies that form the basis for understanding this relationship, and the unique characteristics of melanoma-specific CD8 T cells found in hosts with vitiligo. We also discuss the implications of our recent findings for the interpretation of patient responses, and the design of next-generation cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.